SPRB Stock Price, Spruce Biosciences Inc Quote, Chart

Market Summary

USD0.75-0.02

Market Closed

-2.60%

SPRB Stock Price

View Fullscreen

SPRB RSI Chart

SPRB Valuation

Market Cap

30.9M

Price/Earnings (Trailing)

-0.66

Price/Sales (Trailing)

3.05

Price/Free Cashflow

-0.85

SPRB Price/Sales (Trailing)

SPRB Profitability

Return on Equity

-70.17%

Return on Assets

-53.41%

Free Cashflow Yield

-118.09%

SPRB Fundamentals

SPRB Revenue

Revenue (TTM)

10.1M

Rev. Growth (Qtr)

-30.29%

SPRB Earnings

Earnings (TTM)

-46.8M

Earnings Growth (Yr)

9.12%

Earnings Growth (Qtr)

-16.83%

Breaking Down SPRB Revenue

Last 7 days

-9.6%

Last 30 days

5.6%

Last 90 days

-85.1%

Trailing 12 Months

-66.8%

How does SPRB drawdown profile look like?

SPRB Financial Health

Current Ratio

4.67

Debt/Equity

0.02

Debt/Cashflow

-27.59

SPRB Investor Care

Shares Dilution (1Y)

3.54%

Diluted EPS (TTM)

-1.13

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	10.1M	0	0	0
2023	3.5M	5.5M	8.3M	10.1M
2022	0	0	821.0K	1.5M
2021	0	0	0	119.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Spruce Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 21, 2024	novo holdings a/s	sold	-350,951	0.7547	-465,021	-
Mar 20, 2024	novo holdings a/s	sold	-264,081	0.7336	-359,979	-
Mar 19, 2024	novo holdings a/s	sold	-447,715	0.755	-593,000	-
Mar 18, 2024	novo holdings a/s	sold	-647,008	0.7684	-842,020	-
Mar 14, 2024	novo holdings a/s	sold	-1,698,900	0.8884	-1,912,320	-
Dec 29, 2023	charlton ralph william iii	acquired	9,150	0.9775	9,361	chief medical officer
Dec 29, 2023	gharib samir m.	acquired	11,001	0.9775	11,255	president & cfo
Dec 15, 2023	gharib samir m.	sold (taxes)	-59,917	1.66	-36,095	president & cfo
Dec 15, 2023	gharib samir m.	acquired	-	-	112,250	president & cfo
Dec 15, 2023	szwarcberg javier b.	acquired	-	-	111,000	chief executive officer

Which funds bought or sold SPRB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	61,728	61,728	-%
May 16, 2024	AWM Investment Company, Inc.	new	-	157,180	157,180	0.02%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-79.97	-1,415,260	80,337	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-8.44	-296,990	96,676	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	-182,248	66,802	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-26,000	-	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-18.81	-248,080	69,063	-%
May 15, 2024	MORGAN STANLEY	added	909	10,666	16,916	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	200,900	20,474	20,512	-%
May 15, 2024	ADAR1 Capital Management, LLC	new	-	287,023	287,023	0.06%

Are Funds Buying or Selling SPRB?

Are funds buying SPRB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SPRB

No. of Funds

Unveiling Spruce Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2024	rosalind advisors, inc.	3.67%	1,508,419	SC 13G/A
Mar 28, 2024	novo holdings a/s	3.9%	1,656,000	SC 13D/A
Mar 28, 2024	radoff bradley louis	6.9%	2,825,000	SC 13G
Mar 25, 2024	novo holdings a/s	6.4%	2,756,000	SC 13D/A
Mar 20, 2024	novo holdings a/s	10.9%	4,671,021	SC 13D/A
Mar 18, 2024	novo holdings a/s	15.1%	6,466,020	SC 13D/A
Mar 07, 2024	healthcap viii, l.p.	8.9%	3,685,621	SC 13D/A
Feb 14, 2024	armistice capital, llc	5.48%	2,230,000	SC 13G
Feb 14, 2024	rock springs capital management lp	6.41%	2,609,125	SC 13G/A
Feb 14, 2024	citadel advisors llc	0.2%	6	SC 13G/A

Recent SEC filings of Spruce Biosciences Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
Apr 30, 2024	8-K	Current Report
Apr 25, 2024	SC 13G/A	Major Ownership Report
Apr 05, 2024	ARS	ARS
Apr 05, 2024	DEF 14A	DEF 14A
Apr 05, 2024	DEFA14A	DEFA14A
Mar 28, 2024	SC 13D/A	13D - Major Acquisition
Mar 28, 2024	SC 13G	Major Ownership Report
Mar 25, 2024	4	Insider Trading

Peers (Alternatives to Spruce Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.57	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Spruce Biosciences Inc News

Latest updates

Spruce Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)									(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2021Q4	2021Q3
Revenue	-30.3%	2,000	2,869	3,073	2,165	2,000	1,095	266	154	41.00
Operating Expenses	4.2%	14,635	14,051	16,731	16,137	15,163	12,111	11,557	9,135	11,400
S&GA Expenses	-100.0%	-	2,951	3,237	3,011	3,451	3,272	2,766	2,877	2,793
R&D Expenses	-7.1%	10,317	11,100	13,494	13,126	11,712	8,839	8,791	6,258	8,607
Interest Expenses	-8.5%	97.00	106	119	127	131	129	110	88.00	88.00
Net Income	-16.8%	-11,625	-9,950	-12,354	-12,824	-12,791	-11,144	-11,401	-9,184	-11,447
Net Income Margin	2.4%	-4.63*	-4.74*	-5.89*	-8.72*	-13.39*	-30.32*	-53.86*	-355.39*	-
Free Cashflow	-33.4%	-14,958	-11,209	-12,276	1,993	-11,790	-11,738	-8,580	-9,805	-7,662

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-15.8%	88.00	104	113	126	139	86.00	95.00	105	115	126	135	143	154	163	78.00	-
Current Assets	-16.0%	86.00	102	111	124	137	84.00	93.00	97.00	95.00	92.00	94.00	111	152	160	74.00	5.00
Cash Equivalents	-15.7%	81.00	96.00	99.00	97.00	74.00	24.00	22.00	47.00	23.00	43.00	58.00	78.00	149	157	72.00	4.00
Liabilities	-23.8%	21.00	27.00	28.00	29.00	31.00	17.00	17.00	15.00	15.00	15.00	15.00	13.00	13.00	13.00	14.00	8.00
Current Liabilities	-24.8%	18.00	24.00	24.00	23.00	23.00	12.00	12.00	10.00	9.00	9.00	9.00	7.00	7.00	10.00	10.00	4.00
Long Term Debt	-23.1%	1.00	2.00	2.00	3.00	3.00	3.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	2.00	3.00	3.00
LT Debt, Current	0%	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	0.00	-	-	-	-	3.00	2.00	1.00
LT Debt, Non Current	-100.0%	-	2.00	2.00	3.00	3.00	3.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	2.00	3.00	3.00
Shareholder's Equity	-12.9%	67.00	77.00	85.00	97.00	108	68.00	78.00	89.00	100	111	120	130	141	149	-	-
Retained Earnings	-5.9%	-208	-197	-187	-174	-162	-149	-138	-126	-114	-103	-93.90	-82.50	-70.73	-60.84	-52.50	-31.30
Additional Paid-In Capital	0.6%	275	274	273	272	270	218	218	217	216	215	214	213	211	210	1.00	1.00
Shares Outstanding	0.3%	41.00	41.00	41.00	41.00	40.00	24.00	24.00	23.00	23.00	23.00	23.00	23.00	-	-	-	-
Float	-	-	-	-	75.00	-	-	-	23.00	-	-	-	143	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	-33.4%	-14,958	-11,209	-12,269	1,993	-11,790	-11,738	-8,578	-9,541	-11,826	-9,799	-7,597	-9,694	-8,787	-9,266	-7,597	-4,700	-5,956	-	-
Share Based Compensation	27.9%	1,562	1,221	1,122	1,219	1,060	802	783	905	1,141	797	1,031	1,010	1,120	409	218	96.00	32.00	-	-
Cashflow From Investing	-100.0%	-	9,300	13,993	22,000	10,484	14,569	-16,893	33,507	-7,491	-5,983	-12,335	-60,831	-19.00	-24.00	-43.00	-	-	-	-
Cashflow From Financing	58.9%	-227	-552	-405	-432	50,529	36.00	-90.00	-99.00	-88.00	167	17.00	176	283	94,282	43,197	-99.00	43,655	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SPRB Income Statement

2024-03-31

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration revenue	$ 2,002	$ 1,964
Operating expenses:
Research and development	10,317	11,712
General and administrative	4,318	3,451
Total operating expenses	14,635	15,163
Loss from operations	(12,633)	(13,199)
Interest expense	(97)	(131)
Interest income and other expense, net	1,105	539
Net loss	(11,625)	(12,791)
Other comprehensive gain, net of tax:
Unrealized gain on available for sale securities	0	370
Total comprehensive loss	$ (11,625)	$ (12,421)
Net loss per share, basic	$ (0.28)	$ (0.4)
Net loss per share, diluted	$ (0.28)	$ (0.4)
Weighted-average shares of common stock outstanding, basic	41,096,231	31,900,160
Weighted-average shares of common stock outstanding, diluted	41,096,231	31,900,160

SPRB Balance Sheet

2024-03-31

CONDENSED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 81,154	$ 96,339
Prepaid expenses	3,100	3,876
Other current assets	1,611	1,968
Total current assets	85,865	102,183
Right-of-use assets	1,121	1,181
Other assets	553	582
Total assets	87,539	103,946
Current liabilities:
Accounts payable	1,891	3,332
Accrued expenses and other current liabilities	11,973	14,600
Term loan, current portion	1,622	1,622
Deferred revenue	2,908	4,911
Total current liabilities	18,394	24,465
Lease liabilities, net of current portion	950	1,019
Term loan, net of current portion	1,321	1,717
Other liabilities	250	236
Total liabilities	20,915	27,437
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 41,154,799 and 41,029,832 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	4	4
Additional paid-in capital	275,477	273,737
Accumulated deficit	(208,857)	(197,232)
Total stockholders equity	66,624	76,509
Total liabilities and stockholders’ equity	$ 87,539	$ 103,946

About Spruce Biosciences Inc

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

CEO	Dr. Javier Szwarcberg M.D., M.P.H.
WEBSITE	sprucebiosciences.com
INDUSTRY	Biotechnology
EMPLOYEES	32

Spruce Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Spruce Biosciences Inc? What does SPRB stand for in stocks?

SPRB is the stock ticker symbol of Spruce Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Spruce Biosciences Inc (SPRB)?

As of Fri May 17 2024, market cap of Spruce Biosciences Inc is 30.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SPRB stock?

You can check SPRB's fair value in chart for subscribers.

What is the fair value of SPRB stock?

You can check SPRB's fair value in chart for subscribers. The fair value of Spruce Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Spruce Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SPRB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Spruce Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether SPRB is over valued or under valued. Whether Spruce Biosciences Inc is cheap or expensive depends on the assumptions which impact Spruce Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SPRB.

What is Spruce Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SPRB's PE ratio (Price to Earnings) is -0.66 and Price to Sales (PS) ratio is 3.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SPRB PE ratio will change depending on the future growth rate expectations of investors.